Back to Search Start Over

Cost Effectiveness of Different Initial Antimicrobial Regimens for Elderly Community-Acquired Pneumonia Patients in General Ward.

Authors :
Han X
Chen L
Wang Y
Li H
Wang H
Xing X
Zhang C
Suo L
Wang J
Yu G
Wang G
Yao X
Yu H
Wang L
Liu X
Cao B
Source :
Infection and drug resistance [Infect Drug Resist] 2021 May 18; Vol. 14, pp. 1845-1853. Date of Electronic Publication: 2021 May 18 (Print Publication: 2021).
Publication Year :
2021

Abstract

Purpose: The cost-effectiveness of different guideline-concordant antimicrobial regimens for elderly patients with community-acquired pneumonia (CAP) was rarely discussed. This study attempts to explore the most appropriate cost-effectiveness of guideline-concordant antimicrobial regimen for elderly patients with CAP in general wards.<br />Patients and Methods: This was a multicenter, retrospective, 4:2:1 matched study enrolling 511 elderly patients with CAP hospitalized in general wards. Two hundred ninety-two patients prescribed with β-lactam monotherapy (group A), 146 patients prescribed with fluoroquinolone monotherapy (group B) and 73 patients prescribed with β-lactam/macrolide combination therapy (group C). Clinical outcomes and medical costs were analyzed by χ <superscript>2</superscript> test for categorical variables or Kruskal-Wallis H -test for continuous variables.<br />Results: There were no statistical differences in imaging features, etiology and complications during hospitalization among these three groups. The rates of clinical failure occurrence, in-hospital mortality, 30-day mortality and 60-day mortality also had no significant differences among group A, B and C patients; however, the median length of stay (LOS) in group A patients was 12.0 days, which was significantly higher than that in group B and C patients (both 10.0 days, p<0.02). The median total, drug, and antibiotic costs for one elderly CAP episode in group B patients were RMB 10368.4, RMB 3874.8, and RMB 1796.3, respectively, which were significantly lower than those in group A and C patients (p<0.01).<br />Conclusion: Non-inferiority of clinical failure occurrence and short-term mortality was observed in different guideline-concordant antimicrobial regimens for elderly patients with CAP in general wards; however, the median LOS and hospitalization-associated costs for one elderly CAP episode with fluoroquinolone monotherapy were significantly lowest, and this strategy was considered to be the most cost-effective strategy in general wards.<br />Competing Interests: The authors report no conflicts of interest in this work.<br /> (© 2021 Han et al.)

Details

Language :
English
ISSN :
1178-6973
Volume :
14
Database :
MEDLINE
Journal :
Infection and drug resistance
Publication Type :
Academic Journal
Accession number :
34040398
Full Text :
https://doi.org/10.2147/IDR.S302852